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Abstract
Introduction
Both yaws and trachoma are endemic in the Pacific. Mass treatment with azithromycin is
the mainstay of the WHO strategy for both the eradication of yaws and the elimination of tra-
choma as a public health problem, but the dose recommended for trachoma is lower than
that for yaws. In countries where both diseases are endemic, there is a potential for synergy
between yaws and trachoma control programs if mass treatment with the lower dose of azi-
thromycin was shown to be effective for the treatment of yaws. In an earlier study, we dem-
onstrated a profound reduction in the clinical and serological prevalence of yaws following a
single round of mass treatment with azithromycin 20 mg/kg undertaken for the purposes of
trachoma elimination.
Methods
This survey was conducted 18 months following a single round of azithromycin mass treat-
ment in the same communities in which we had conducted our previous six-month follow-up
survey. We examined children aged 1–14 years and took blood and lesion samples for
yaws diagnosis using the Treponema pallidum particle agglutination assay (TPPA) and the
non-treponemal Rapid Plasma Reagin (RPR) test.
Results
A total of 1,284 children were enrolled in the study. Amongst children aged 5–14 years, 223
had a positive TPPA (27.5%, 95% CI 13.6–47.7%). The TPPA seroprevalence amongst
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this age group did not differ significantly from either our pre-mass treatment survey or our
initial follow-up survey. Thirty-five children had positive TPPA and positive RPR (4.3%, 95%
CI 2.1–8.7%), and this did not differ significantly from our initial post-mass drug administra-
tion (MDA) follow-up survey (4.3% versus 3.5%, p = 0.43) but remained significantly lower
than our initial pre-MDA survey (4.3% vs 21.7%, p <0.0001). Village-level MDA coverage
was strongly associated with dual-seropositivity (p = 0.005). Amongst children aged 1–4
years, 16 had a positive TPPA (3.5%, 95% CI 1.6–7.1%). This did not differ significantly
from the seroprevalence in this age group that had been predicted based on our previous
surveys (3.5% vs 5%, p = 0.11). Fourteen children (1.1%) were considered to have a skin
lesion clinically consistent with yaws, but none of these individuals was seropositive for
yaws. Of nine cases where a swab could be collected for PCR, all were negative for Trepo-
nema pallidum subsp. pertenue DNA.
Discussion
In this study we have shown that the benefit of a single round of mass treatment with azithro-
mycin 20mg/kg appears to extend to 18 months without any further intervention. The lack of
a significant change in seroprevalence from 6 to 18 months after mass treatment might sug-
gest that interventions could be spaced at yearly intervals without a significant loss of
impact, and that this might facilitate integration of yaws eradication with other neglected
tropical disease (NTD) control programmes. MDA coverage above 90% was associated
with significantly better outcomes than coverages lower than this threshold, and strategies
to improve coverage at all stages of yaws eradication efforts should be investigated.
Author Summary
Yaws is a neglected tropical disease caused by a bacterium closely related to the agent of
syphilis. Mass treatment is recommended by WHO for the control of both yaws and the
blinding eye disease trachoma, but the dose used for trachoma is lower (20 mg/kg versus
30 mg/kg). We have previously shown that a single round of mass treatment with azithro-
mycin for trachoma had a significant impact on the number of cases of yaws in a commu-
nity, suggesting that the lower dose of azithromycin might be effective for yaws and that
trachoma and yaws programmes in the Pacific might be integrated. We repeated our sur-
vey 18 months following the initial round of mass treatment to see if the benefit seen at 6
months had persisted. In this study, the number of yaws cases remained significantly
lower than before mass treatment even without any additional public health interventions
taking place in the 18 months between MDA and this follow-up. This might suggest that
annual mass treatment could be used rather than the current recommendation of six
monthly treatment. An annual treatment strategy might facilitate integrating yaws eradi-
cation efforts with other NTD control programmes.
Introduction
Yaws is an endemic treponemal disease caused by Treponema pallidum subsp pertenue [1].
Most cases of yaws are seen in rural communities in tropical countries [2] and are manifest as
lesions of the skin, bones and joints. In 2012, single dose azithromycin was shown to be an
18-Month Follow-Up of Trachoma MDA on Yaws
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effective treatment for yaws [3], and mass treatment with azithromycin was subsequently
adopted by WHO as the cornerstone of a new yaws eradication campaign [4]. Active yaws is
usually seen in children aged 5–14 years, and examination of this age group has been used in
many studies to assess the prevalence of active yaws [5–7]. WHO also recommends surveil-
lance by serology of children aged 1–4 years to determine whether transmission has been inter-
rupted [4].
The Pacific is a particular focus for yaws with a large number of cases reported in Papua
New Guinea, the Solomon Islands and Vanuatu [2]. Trachoma, caused by ocular infection with
Chlamydia trachomatis, is also endemic in the Pacific. As community mass treatment with azi-
thromycin is also central to the control of trachoma [8], there is the potential for synergies
between trachoma and yaws programmes in the Pacific [9]. A challenge is the difference in the
dose of azithromycin recommended for trachoma (20mg/kg, max 1g) compared to yaws
(30mg/kg, max 2g). We previously demonstrated that the prevalence of active and latent yaws
declined markedly six months after a single round of mass treatment with azithromycin given
as part of a trachoma control program in the Solomon Islands [10], providing the first evidence
that low dose azithromycin is an effective intervention to reduce the community prevalence of
yaws.
The optimal number and timing of rounds of mass treatment needed to interrupt transmis-
sion of yaws are unknown [11], although pilot data from other countries suggest that a single
round is inadequate [7]. In 2015 a decision was made not to undertake a second round of azi-
thromycin mass treatment in the Solomon Islands in light of a low reported prevalence of tra-
chomatous trichiasis and a low prevalence of ocular infection with C. trachomatis [12]. This
provided an opportunity to assess any potential rebound in active and latent yaws in the
absence of further control measures. It was hoped that these data might inform expansion of
yaws control efforts and, in particular, any potential for synergy between yaws and trachoma
control programs in the Pacific. We therefore conducted an 18 month follow-up survey to
assess whether the seroprevalence of yaws has changed significantly in the absence of any fur-
ther intervention.
Methods
This survey was conducted 18 months following a single round of azithromycin mass treat-
ment (20mg/kg) conducted by the Solomon Islands Ministry of Health and Medical Services.
The study was conducted in the same communities in which we had conducted our previous
six month follow-up survey [10]. No further rounds of mass treatment (or any other specific
interventions against yaws including case finding surveys and targeted total treatment) had
been conducted in these communities since then.
For each household we collected data on the number of residents. We enrolled children
aged 1–14 years for assessment, collecting individual level data on age, gender, the presence or
absence of clinical signs and symptoms of yaws and yaws treatment history. We categorized
skin lesions using the WHO yaws pictorial guide [13]. All data were entered directly into
Android smartphones using the ODK software package [14].
For children aged 5–14 years, venepuncture was performed and a serum sample collected.
In children aged 1–4 years a finger-prick blood sample was collected onto a filter paper. Filter
papers were air-dried and stored in sealed bags with desiccant sachets. From individuals with
ulcerative or papillomatous skin lesions, we also collected a swab sample of lesion exudate.
Exudate was transferred to a FTA Elute Micro Card (GE Healthcare, Buckinghamshire, UK)
using three firm side-to-side motions of the swab across the card. Each card was placed in its
own re-sealable plastic packet with an individual desiccant sachet. The samples were
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transferred to the National Referral Hospital in Honiara, where they were frozen at -20°C, and
shipped to the London School of Hygiene & Tropical Medicine (LSHTM), UK, and the Centers
for Disease Control and Prevention (CDC), USA, on dry-ice for testing.
Laboratory Testing
Blood samples were tested at LSHTM. Filter paper samples were eluted and tested using the
Treponema pallidum particle agglutination test (TPPA, Mast Diagnostics, Merseyside UK) as
previously described [15]. For serum samples a TPPA test was performed initially and for sam-
ples that were TPPA-positive, a quantitative rapid plasma reagin test (RPR, Deben Diagnostics,
Ipswich, UK) was performed.
Lesion swab samples were tested at the CDC using a number of multiplex real-time (RT)
PCR assays. Initially samples were tested using an assay for the identification of T. pallidum
subspecies DNA [5]. If the PCR was positive for T. pallidum subsp. pertenue this was followed
by a second multiplex RT PCR to detect mutations in the 23S rRNA gene which are associated
with azithromycin resistance. All samples were also tested with a duplex RT PCR for the detec-
tion ofHaemophilus ducreyi andMycobacterium ulcerans [16]. All laboratory testing was per-
formed by individuals masked to the clinical findings.
Statistical Analysis
In children aged 1–4 years, a positive TPPA was taken as evidence of previous or current yaws
infection. For children aged 5–14 years, a positive TPPA was considered as evidence of previ-
ous or current yaws infection. We considered individuals with clinical signs of yaws and both a
positive TPPA and an RPR titre of1:4 (dual-seropositivity) to have active yaws. We consid-
ered individuals who were dual-seropositive but without clinical signs of yaws to have latent
yaws. For the purpose of the analysis an RPR titre of1:16 was considered to be a high-titre
positive. We classified household size as5 or>5 residents, 5 householders being the national
average according to the most recent census [17]. For each community, we used village level
estimates of treatment coverage obtained during our previous six month follow up survey [10].
We classified village level coverage as low (<80%), high (80–90%) or very high (>90%). We
calculated the prevalence of latent and active yaws in older children (aged 5–14 years) and the
sero-prevalence of exposure to yaws in younger children (aged 1–4 years). Logistic regression
was used to estimate unadjusted and adjusted odds ratios (ORs) for factors associated with
both TPPA- and dual-seropositivity. Robust standard errors were used to calculate all confi-
dence intervals (CIs) and p-values, to account for village-level clustering. All analyses were per-
formed using Stata 13.1 (Statacorp, Texas).
Sample Size
In our previous follow-up survey, the seroprevalence of yaws infection was 3.6%. We calculated
that a sample size of 738 was need to measure a seroprevalence of 4% with a degree of absolute
precision of 3%, assuming a design effect of 4.5 (estimated using data from the baseline survey)
in children aged 5–14 years. Based on previous pre-MDA data from 5–14 year old children we
hypothesized that the seroprevalence amongst children aged 1–4 years would be approximately
1% if transmission had been interrupted following the earlier community mass treatment and
5% if transmission had not been interrupted. We calculated that a sample size of 432 children
aged 1–4 years was required to detect a prevalence of 1% with a precision of 2% and a design
effect of 4.
18-Month Follow-Up of Trachoma MDA on Yaws
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Ethical Approval
Written informed consent was obtained from each participating child’s parent or guardian by
a member of staff fluent in the local dialect. Assent was obtained from children. Ethical
approval for the study was granted by the ethics committees of the Solomon Islands MHMS,
the CDC, and LSHTM.
Results
A total of 1,284 children were enrolled from 519 households in 10 communities.
811 children were aged 5–14 years (median 9 years), of whom 401 (49.4%) were male
(Table 1). A serum sample was collected from 770 children (94.9%). Thirty-one children
(3.8%) declined collection of a serum sample but assented to collection of a dried-blood spot,
whilst 10 children (1.2%) assented to examination but not to sample collection. 473 children
aged 1–4 years (median 3 years) were also enrolled, of whom 248 (52.4%) were male. A dried
blood spot was collected from 451 children (95.3%) in this age group. Seven children (1.5%)
aged under 5 incorrectly had a serum sample (rather than a DBS) collected. No dried blood
spot was collected from 15 children aged under 5 (3.2%).
Four hundred and thirty seven children (34.0%) had at least one skin lesion. 14 children
(1.1%) had lesions considered to be clinically consistent with yaws. The most common non-
yaws lesions were scabies and impetigo, as previously reported (A Steer, Personal Communica-
tion). As in our initial 6 month follow-up survey, no individual with a skin lesion consistent
with yaws had dual-positive serology. Swabs were obtained from nine yaws-like lesions. Swabs
could not be obtained from the other three lesions as they were dry/crusted. Of these lesion
samples, all were negative on RT-PCR for T.p subsp pertenue and two were positive for H.
ducreyi.
Amongst 5–14 year-old children, 223 had a positive TPPA (27.5%, 95% CI 13.6–47.7%).
The TPPA seroprevalence amongst this age group did not differ significantly from either our
pre-MDA survey or our initial follow-up survey (31.4% and 25.0% respectively, p>0.05 for
both comparisons). In both the crude and adjusted analyses, only age was associated with
TPPA positivity (Table 2). Thirty-five children had dual positive serology (4.3%, 95% CI 2.1–
8.7%), of whom 8 had high-titre positive serology. This did not differ significantly from our
initial post-MDA follow-up survey (4.3% vs 3.5%, p = 0.43) but remained significantly lower
than our initial pre-MDA survey (4.3% vs 21.7%, p <0.0001). The level of MDA coverage
was strongly associated with dual-seropositivity (p = 0.005). Compared to an MDA coverage
above 90%, a village level coverage below 80% was strongly associated with an increased risk
of dual-seropositivity (aOR 6.95, 95% CI 1.2–38.3, p = 0.03) (Table 3). Coverage of between
80–90% was also associated with an increased risk of dual-seropositivity compared to cover-
age >90%, but this difference was not statistically significant (aOR 3.99, 95% CI 0.66–24.0,
p = 0.12).
Table 1. Demographics of study subjects.
Number of Children 1284
Number of Households 519
Household Size [Number of residents] (Median, IQR) 6 (4–8)
Age [years] (Median, IQR) 6 (3–10)
Village Level azithromycin Coverage Low (<80%) 536 (41.7%)
High (80–90%) 501 (39.0%)
Very High (>90%) 247 (19.2%)
doi:10.1371/journal.pntd.0004927.t001
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Amongst children aged 1–4 years, 16 had a positive TPPA (3.5%, 95% CI 1.6–7.1%) includ-
ing two children aged less than two years (0.9%, 95% CI 0.2–4.0%). This did not differ signifi-
cantly from the seroprevalence in this age group that had been predicted based on our previous
surveys (3.5% vs 5%, p = 0.11). In villages where very high (>90%) mass treatment coverage
was achieved, there were no young children with a positive TPPA, compared to 3.8% and 4.4%
TPPA positivity in villages with low (<80%) and high (80–90%) coverage of mass treatment,
respectively, although these differences were not statistically significant (p = 0.08 and 0.06
respectively). Age was the only variable significantly associated with TPPA seropositivity
amongst children aged 1–4 years (Table 4).
Discussion
We have previously demonstrated that a single round of mass treatment with azithromycin at
20mg/kg, given for the purposes of trachoma control, has a significant impact on the preva-
lence of yaws-like skin lesions and sero-positivity for yaws [10]. In this study we have shown
Table 2. Risk factors for TPPA Positivity amongst children aged 5–14 years.
Variable Indicative Prevalence Data Unadjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio#
(95% CI)
p-value
Age [years] 5-9: 19% 1.22 * (1.13-1.32) 1.22 (1.13-1.32) <0.001
10-14: 38.5%
Male Male: 28.4% 1.09 (0.77-1.57) 1.19 (0.87-1.63) 0.24
Female: 26.6%
Household Size [number of residents] 5: 30.21% 1
>5: 25.6% 0.8 (0.48-1.31) 0.75 (0.46-1.23) 0.23
Village Level azithromycin coverage¶ Low Coverage (<80%): 24.1% 1.13 (0.23-5.48) 1.28 (0.26-6.39) 0.73
High Coverage (80-90%): 33.4% 1.83 (0.34-10.09) 1.96 (0.31-12.56) 0.44
Very High Coverage (>90%): 21.9% 1
* Increased odds associated with each one year increase in age
# Adjusted for age and gender
¶ Compared to very high coverage (>90%)
doi:10.1371/journal.pntd.0004927.t002
Table 3. Risk factors for Dual-Seropositivity amongst children aged 5–14 years.
Variable Indicative Prevalence Data Unadjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio#
(95% CI)
p-value
Age [years] 5-9: 3.3% 1.18* (1.05-1.34) 1.19 (1.08-1.35) 0.009
10-14: 5.7%
Male Male: 3.2% 1.77 (0.85-3.71) 1.91 (0.93-3.94) 0.07
Female: 5.5%
Household Size [number of residents] 5: 5.7% 1
>5: 3.3% 0.57 (0.14-2.32) 0.53 (0.13-2.14) 0.33
Village Level azithromycin coverage¶ Low Coverage (<80%): 6.2% 5.5 (0.97-31.22) 6.95 (1.27-38.3) 0.03
High Coverage (80-90%): 4.1% 3.6 (0.58-21.67) 3.99 (0.66-24.0) 0.12
Very High Coverage (>90%): 1.2% 1
* Increased odds associated with each one year increase in age
# Adjusted for age and gender
¶ Compared to very high coverage (>90%)
doi:10.1371/journal.pntd.0004927.t003
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that the benefit appears to extend to 18 months without any further intervention. The WHO
yaws eradication strategy [4] suggests that, following initial mass treatment, follow-up surveys
with targeted treatment of cases and contacts should take place every 3–6 months. This
requirement for at least biannual intervention is a potential barrier to integrating yaws eradica-
tion efforts with other NTD control programmes, including trachoma, where annual mass
treatment is recommended. The absence of any active cases of yaws in these communities and
the lack of a significant change in seroprevalence from 6 to 18 months after mass treatment
might suggest that interventions could be spaced at yearly intervals without a significant loss of
impact. Consistent with these findings we have previously reported a decline in the number of
routinely reported cases of yaws in Western provinces following MDA [10]. In 2013 Western
province reported 5,231 cases of yaws and this declined to 3,018 in 2014 and 2,252 cases in
2015. This routine reporting data supports our finding that the impact of MDA has been sus-
tained up to 18 months.
Modelling studies exploring the optimal spacing of MDA are under way, and initial results
suggest that such decisions are highly dependent on the basic reproductive number (R0) of
yaws. Where R0 is low (<1.45) then annually spaced treatment may be sufficient to achieve
interruption of transmission (MMarks–Manuscript submitted).
Of particular interest, the village-level treatment coverage was the strongest risk factor for
dual-seropositivity 18 months after mass treatment. When the coverage was below 80%, the
risk for seropositivity was more than 6 times greater compared to villages where coverage of
greater than 90% was achieved. Consistent with these findings in older children, we noted
that in villages where very high (>90%) coverage was achieved there were no seropositive
children aged 1–4 years, which may indicate that transmission was interrupted in these com-
munities. Ongoing presumed seroconversion, including in children aged 2 years or less, was
documented, however, in villages with coverage below 90%. We cannot exclude the possibil-
ity that positive serology in children aged 1–4 years was due to mother-to-child transmission
of syphilis. However, in the context of ongoing transmission of yaws amongst older children
in these communities, we consider it likely that seropositivity amongst children aged 1–4
years does reflect ongoing transmission of yaws in this age group. These two findings empha-
size the need for extremely high coverage during mass treatment. Given the difficulties that
can be faced in achieving such high coverage at a programmatic level [18], innovative strate-
gies should be considered to augment yaws eradication efforts. This might include additional
school based mass treatment alongside community based approaches, or use of multiple
rounds of mass treatment before transitioning to the total targeted treatment phase of the
yaws eradication strategy [4].
Table 4. Risk factors for TPPA Positivity amongst children aged 1–4.
Variable Indicative Prevalence Data Unadjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio#
(95% CI)
p-value
Age [years] 1-2: 0.87% 1
3-4: 5.8% 2.21* (1.55-3.15) 2.23 (1.51-3.29) 0.001
Male Male: 4.0% 1.53 (0.58-4.06) 1.64 (0.56-4.82) 0.33
Female: 2.7% 1
Household Size [number of residents] 5: 4.0% 0.72 (0.25-2.08) 0.78 (0.25-2.35) 0.62
>5: 2.9% 1
* Increased odds associated with each one year increase in age
# Adjusted for age and gender
doi:10.1371/journal.pntd.0004927.t004
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Our data add to the literature supporting a lower dose of azithromycin (20mg/kg max 1g vs
30mg/kg max 2g) for the treatment of yaws. If a lower dose is proven effective this may help
achieve programmatic synergies, especially in the Pacific where several countries have a high
prevalence of yaws, and trachoma is also endemic. AWHO sponsored trial (NCT02344628) is
being undertaken in Ghana and Papua New Guinea to formally compare the efficacy of these
two doses in both active and latent yaws, and it is hoped that this study will provide a definitive
answer on the efficacy of the lower dose of azithromycin. The prevalence of ulcers caused by
Haemophilus ducreyi remained lower than in our pre-MDA study but has not fallen as
markedly as that of yaws ulcers. We also noted a large number of ulcers of an unclear aetiology
and further studies are required to better understand other causes of ulcers in a post-MDA
setting.
The major limitation of our study is the observational design. A study of mass treatment in
Papua New Guinea found only 44 serologically confirmed active cases in a total population of
13,166 individuals seen at six months follow-up. Given the smaller sample size of this study, we
may have been underpowered to detect rare active cases following the initial round of mass
treatment. A larger sample size would also have allowed more precise estimates of the seroprev-
alence of infection in both age groups but would probably not have altered the major findings
of this study.
Our data show that the impact of a single round of mass treatment on yaws prevalence is
profound, and appears to last for at least 18 months following mass treatment even in the
absence of further interventions. We have demonstrated that mass treatment coverage above
90% is associated with significantly better outcomes than lower coverage. Strategies to improve
coverage at all stages of yaws eradication efforts should be investigated.
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